Just 1 minimally-invasive injection relieves pain and inflammation for up to 1 year2 

Synovetin OA®—Targets Synovial Inflammation1


reduction in inflammatory mediators

Synovetin OA® is revolutionizing the treatment of arthritis in dogs' elbows

reduction in inflammatory mediators

The active agent of Synovetin OA® is Tin-117m, a unique conversion electron therapeutic veterinary device3

Synovetin OA
  • Targeted therapy: tin-117m (novel radio-isotope)
  • Reduces synovitis and relieves chronic canine elbow OA pain
  • Targets pro-inflammtory macrophages
  • Very long-lasting -- up to one year with only one IA injection
  • Just once a year, IF NEEDED
  • No systemic or local side effects; a veterinary device, not a drug
  • Minimally-invasive, outpatient procedure
  • Multimodal

Synovetin OA® redefines conservative management of chronic OA— transforming the treatment approach with 1 minimally-invasive procedure that provides safety and long-term efficacy.2

Synovetin OA® transforms the treatment of canine osteoarthritis1

Improves mobility so dogs can be life-loving pets again


icon dog

Restores active lifestyle

icon joint

Provides durable pain and inflammation relief

icon change

Alters the treatment of chronic OA

Synovetin OA

Effectiveness was demonstrated in a multi-center study2

Sites included Gulf Coast Veterinary Specialists, Louisiana State University School of Veterinary Medicine, and University of Missouri College of Veterinary Medicine.

3 validation metrics confirm formidable and durable treatment effect:

  • Effectiveness evaluated in Grade 1 & 2 and Grade 3 elbow OA
  • Dogs were given a single injection in 1 or 2 elbows and followed for 12 months
  • Study population included 69 dogs and 92 elbows

Images of synovitis and administration of Synovetin OA® are courtesy of Dr. Caleb Hudson, DVM, DACVS and Dr. Michelle Fabiani, DVM DACVR, Gulf Coast Veterinary Specialists


Synovetin OA® is an effective new tool in treating canine elbow osteoarthritis (OA).

Overall Treatment Success2*

Dogs with Grade 1 & 2 Elbow OA—


1 elbow treated; n=12/13

Dogs with Grade 3 Elbow OA—


Both elbows treated; n=10/14

*Overall treatment success based on a composite of force plate, Canine Brief Pain Inventory (CBPI), and clinician lameness assessments for the label dose.

Clinician’s lameness assessment—
Grade 1 & 2 Elbow OA

Dogs given the label dose had a mean reduction in overall lameness score from baseline at each post-treatment interval—1, 3, 6, 9, and 12 months2

9 to 12 months

Reductions in mean clinician’s lameness assessment scores for dogs with Grade 3 elbow OA were seen at 3, 6, and 9 months


Force plate gait analysis—Grade 1 & 2 Elbow OA

82% of dogs showed significant increase in peak vertical force and/or mean vertical impulse after just 1 injection.


Measurements taken at 1, 3, 6, 9, and 12 months.
Treatment Success = an improvement in PF and/or IMP during follow-up visit compared to baseline. n=22 dogs
PF=peak vertical force;
IMP=mean vertical impulse

jumping dog

Canine brief pain inventory instrument—Grade 1 & 2 and Grade 3 Elbow OA2

In Grade 1& 2 OA, mean PSS and PIS scores showed statistically significant improvement at all time intervals compared to baseline

There was statistical agreement between clinician and pet owner assessments.2

§ Brown D. Canine Brief Pain Inventory User Guide, 2017. No measurements were taken at Month 1 for Grade 3 elbow OA dogs.
PSS=pain severity score;
PIS=pain interference score
§Results at label dose

Pet Parents reported 12 months of sustained efficacy


Synovetin OA® provides targeted, non-systemic therapy.1


  1. Donecker JM, Stevenson NR. Radiosynoviorthesis: A new therapeutic and diagnostic tool for canine joint inflammation. Technical Bulletin. Exubrion Therapeutics, Inc. July 2019.
  2. Data on File, Exubrion Therapeutics®.
  3. Fox SM, Donecker JM. Synovitis. Technical Bulletin. Exubrion Therapeutics®, July 2019.


No clinically significant device-related adverse effects reported with Synovetin OA®1,2

Reimagines success in treating chronic OA


Synovetin OA® provides targeted, non-systemic therapy3


The optimal-sized (~2-20 microns) particles are small enough to be engulfed by macrophages, but large enough to remain in the joint space.4

  • Therapeutic conversion electrons have a range of only 300 microns (0.3mm)4
  • Tin-117m decays to harmless microparticles of inert tin and is removed from the body via lymphatics while clinical response continues1

In an evaluation of the biodistribution and clinical effects in normal hound dogs (n=5)…


Autoradiography showed Synovetin OA® was localized in synoviocytes throughout all treated elbow joints.1

Safety was demonstrated throughout the clinical trial program1,2

Laboratory, excretion, and dosimetry results were unremarkable for all dogs tested1

icon microscope

No pathologic changes to articular cartilage or bone

icon clipboard

No significant adverse effects were noted, even in a missed injection

icon lifesaver

No safety issues were identified by either pet parents or medical personnel

Targeted local treatment with Synovetin OA® avoids systemic adverse side effects of other treatments4

icon pills

vs systemic therapies
Avoids toxicity of NSAIDs, piprants, or immunosuppressives

icon injection

vs IA corticosteroids
Avoids cartilage toxicity

icon surgery

vs surgical resection
Minimally invasive; low bleeding risk

Synovetin OA® can be safely and effectively used in conjunction with many other multimodal treatments.1*

Treated dogs can return home same day as treatment2,5†

  • Dogs are free to resume all normal activities as they are able, like walking or running
  • No labeled need for restraint
  • Counsel pet parents to follow release instructions
    • There are guidelines on the amount of time that can be spent in close proximity for at least 2 weeks following treatment

*Clinical studies of Synovetin OA® did not exclude other OA treatments; consequently, a number of dogs received other treatments sporadically during the 12-month studies.
†Please see release instructions.

Synovetin OA® can be re-administered annually after a previous treatment for easy, long-term control of chronic OA and ongoing patient relationships.

Synovetin OA® delivers sustained, long-term OA relief.1

Schedule a Presentation with Your Local Rep


  1. Data on File, Exubrion Therapeutics®.
  2. Lattimer JC, Selting KA, Lunceford JM, et al. Intraarticular injection of a Tin-117m radiosynoviorthesis agent in normal canine elbows causes no adverse effects. Vet Radiol Ultrasound. 2019:1-8. doi: 10.1111/vru.12757.
  3. Fox SM, Donecker JM. Synovitis. Technical Bulletin. Exubrion Therapeutics®, July 2019.
  4. Donecker JM, Stevenson NR. Radiosynoviorthesis: A new therapeutic and diagnostic tool for canine joint inflammation. Technical Bulletin. Exubrion Therapeutics®, July 2019.
  5. Wendt RE, Stevenson NR, Donecker JM, Doerr C. External radiation exposure following SN-117m colloid intra-articular injections. Poster 1220. Presented at SNMMI, Philadelphia, June 26, 2017.